Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

Resistance to imatinib has been recurrently reported in systemic mastocytosis (SM) carrying exon 17 KIT mutations. We evaluated the efficacy and safety of imatinib therapy in 10 adult SM patients lacking exon 17 KIT mutations, 9 of which fulfilled criteria for well-differentiated SM (WDSM). The Worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez-Twose, Iván, Matito, Almudena, Morgado, José Mário, Sánchez-Muñoz, Laura, Jara-Acevedo, María, García-Montero, Andrés, Mayado, Andrea, Caldas, Carolina, Teodósio, Cristina, Muñoz-González, Javier Ignacio, Mollejo, Manuela, Escribano, Luis, Orfao, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620310/
https://www.ncbi.nlm.nih.gov/pubmed/28978170
http://dx.doi.org/10.18632/oncotarget.10711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620310/
https://www.ncbi.nlm.nih.gov/pubmed/28978170
http://dx.doi.org/10.18632/oncotarget.10711

Ejemplares similares